Skip to content

Benefits of a IMB skills model-based multimodal nursing program on adherence of sublingual immunotherapy in patients with allergic rhinitis: a quasi-experiment study

Benefits of a IMB skills model-based multimodal nursing program on adherence of sublingual immunotherapy in patients with allergic rhinitis: a quasi-experiment study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046723
Enrollment
Unknown
Registered
2021-05-27
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

experimental group:a IMB skills model-based multimodal nursing program
control group:routine nursing program

Sponsors

Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. AR patients who meet the diagnostic criteria of "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis" (2015, Tianjin); 2. The result of skin prick test was positive for antigen, dust mite was the main allergen, and no antihistamine was taken within 1 week; 3. For the first time sublingual immunotherapy, the sublingual immunotherapy drug is Changdi; 4. At least 18 years old; 5. Patients with informed consent, voluntarily participate in this study and actively cooperate.

Exclusion criteria

Exclusion criteria: 1. Those who have a history of mental illness and cognitive dysfunction; 2. Patients with chronic diseases, such as eczema, asthma, diabetes, hypertension, etc.

Design outcomes

Primary

MeasureTime frame
Medication compliance;

Secondary

MeasureTime frame
Medication belief;Self-efficacy;Knowledge level of medication;

Countries

China

Contacts

Public ContactWang Qian

Shanxi Medical University

305091414@qq.com+86 19834517568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026